Amgen (AMGN) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Amgen
Is Amgen a buy right now? The alternative data leans yes. This AMGN stock analysis is built on the 25+ alternative data signals AltIndex tracks on Amgen every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 64/100: a Buy. The stock trades at $417.20 with a $222B market cap.
What’s driving the buy signal over the past 90 days: revenue up 5.8% YoY to $8.6B, web traffic up 15.8% to 544K monthly visits, and Reddit mentions up 100.0% to 2 a day. Stocks scoring above 60 have historically outperformed the S&P 500 over the following six months.
AMGN’s broader alt-data profile also covers job postings (1,000 open roles), headcount (41K employees, according to LinkedIn), business outlook (66% of employees positive), and X followers (119K). Every signal links to its own page with full history, the AMGN technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on AMGN is just below.
Amgen AI Stock Analysis
, headquartered in Thousand Oaks, California, is among the world's largest independent biotechnology firms. Founded in 1980, the company focuses on innovative solutions in the field of human therapeutics, primarily in areas of cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation.
Analysis generated August 1, 2026.
Recent Amgen Stock Alerts
|
Amgen | August 6 Tommy Tuberville (member of U.S. congress) is selling shares |
|
Amgen | August 5 Price is up by 6.3% in the last 24h. |
|
Amgen | July 9 Ro Khanna (member of U.S. congress) is buying shares |
|
Amgen | July 1 Employee Rating is up by 2.7% over the last month. |
Amgen Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 544K | 15.8% | |
| Job Posts | 1K | 0% | |
| LinkedIn Employees | 41K | 3.5% | |
| Employee Recommend | 65 | 3.0% | |
| Business Outlook | 66 | 2.9% | |
| Lobbying Cost | $1.2M | 0% | |
| Sentiment | 100 | 29.9% | |
| Reddit Mentions | 2 | 100.0% | |
| X Mentions | 9 | 0% | |
| Stocktwits Mentions | 57 | 185.0% | |
| News Mentions | 0 | 100.0% | |
| Stocktwits Subscribers | 15K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 119K | 0% | |
| Instagram Followers | 40K | 4.6% | |
| Youtube Subscribers | 40K | 1.5% | |
| Facebook Followers | 36K | 0% | |
| Facebook Engagement | 110 | 55.6% |
About Amgen (AMGN)
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
| Price | $417.20 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $222B |
| Year Range | $265 – $417 |
| Dividend Yield | 0% |
| PE Ratio | 25.5 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Amgen News
View more → |
Amgen gains after strong quarterly results and continued product momentumAugust 5 - Biztoc.com |
 |
Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter SmashAugust 5 - Biztoc.com |
Amgen Q2 2026 earnings beat, raises full-year outlook, drops AMG 513August 5 - Quartz India |
|
 |
Amgen drops ph. 1 obesity drug, upping pressure on MariTideAugust 4 - Biztoc.com |
 |
Amgen Q2 revenue tops projections at $10.1B, up 10%August 4 - Biztoc.com |
Amgen Earnings & Financial Performance
View all earnings →Amgen Insider Trading Activity
View all →| Grygiel Nancy A. filed to sell 7,009 shares at $0.0. May 4 '26 |
| Santos Esteban filed to sell 76,618 shares at $0.0. Feb 26 '26 |
| Santos Esteban filed to sell 76,618 shares at $0.0. Feb 26 '26 |
| Busch Matthew C. filed to sell 3,423 shares at $0.0. Feb 19 '26 |
| Grygiel Nancy A. filed to sell 7,225 shares at $0.0. Nov 20 '25 |
Amgen Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Tommy Tuberville |
Aug 5, 26 | Sell | $33K+ |
| Ro Khanna |
Jul 8, 26 | Buy | $8K+ |
| David Taylor |
Jun 15, 26 | Buy | $8K+ |
| Maria Elvira Salazar |
May 11, 26 | Sell | $33K+ |
| Mark Warner |
May 1, 26 | Sell | $8K+ |
Stocks Similar to Amgen
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Thermo Fisher ScientificTMO |
$599.69 1.0% | $220B | 59 |
 |
Gilead SciencesGILD |
$133.06 0.1% | $165B | 58 |
 |
NovartisNVS |
$156.79 0.3% | $297B | 40 |
 |
Vertex PharmaceuticalsVRTX |
$523.91 5.6% | $126B | 54 |
 |
RegeneronREGN |
$808.05 3.0% | $81B | 57 |
Explore Amgen Data
Frequently Asked Questions: Amgen (AMGN)
Amgen has an AltIndex AI Score of 64/100 (Buy). The score reflects positive alternative data signals. All investments carry risk.
64/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Amgen (AMGN) stock is $417.20 with a market cap of $222B.
As of today, Amgen’s PE (Price to Earnings) ratio is 25.5.
View the latest Amgen insider transactions to see recent buying and selling activity by company executives and directors.
Check the Amgen congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The AMGN stock price chart above shows Amgen’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Amgen technical analysis for RSI, moving averages, and more.
See the stocks similar to Amgen section on this page for companies in the same industry ranked by market cap and AI Score.
